首页> HemaSphere> Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia.

Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia.

导出 LinkOut

翻译打印收藏纠错

第一作者： Christine E,Ryan

第一单位： Department of Medical Oncology Dana-Farber Cancer Institute Boston Massachusetts USA.

作者： Christine E,Ryan ^[1] ; Yue,Ren ^[2] ; Svitlana,Tyekucheva ^[3] ; Jon E,Arnason ^[4] ; Adam M,Boruchov ^[5] ; Caron A,Jacobson ^[1] ; David C,Fisher ^[1] ; Hari,Miskin ^[6] ; Peter,Sportelli ^[6] ; Jennifer R,Brown ^[1] ; Matthew S,Davids ^[1]

作者单位： Department of Medical Oncology Dana-Farber Cancer Institute Boston Massachusetts USA. ^[1] Department of Data Science Dana-Farber Cancer Institute Boston Massachusetts USA. ^[2] Department of Data Science Dana-Farber Cancer Institute Boston Massachusetts USA.;Department of Biostatistics Harvard TH Chan School of Public Health Boston Massachusetts USA. ^[3] Department of Medical Oncology Beth Israel Deaconess Medical Center Boston Massachusetts USA. ^[4] Cancer Institute, Nuvance Health Danbury Connecticut USA. ^[5] TG Therapeutics New York USA. ^[6]

DOI 10.1002/hem3.70067

PMID 39816532

发布时间 2025-07-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

HemaSphere

2025年9卷1期

e70067页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

HemaSphere

2025年9卷1期

e70067页

检索历史清除

Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia.

HemaSphere

相似文献

同项目论文

HemaSphere

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia.

HemaSphere

相似文献

同项目论文

HemaSphere

相关期刊

检索历史清除